Bausch Health Companies Inc. Will Release First-Quarter 2022 Financial Results On May 10 Pharmaceutical Investing
European Commission Approves Merck's KEYTRUDA® for Patients With Microsatellite Instability-High or Deficient Mismatch Repair Tumors in Five Different Types of Cancer Life Science Investing
European Commission Approves Merck's KEYTRUDA® Plus Chemotherapy, With or Without Bevacizumab, for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 Life Science Investing
AUPH SHAREHOLDER ALERT: Jakubowitz Law Reminds Aurinia Pharmaceuticals Inc. Shareholders of a Lead Plaintiff Deadline of June 14, 2022 Pharmaceutical Investing
U.S. Food and Drug Administration Approves Camzyos for the Treatment of Adults With Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms Pharmaceutical Investing
Kessler Topaz Meltzer & Check, LLP - Important Reminder for AbbVie, Inc. Investors of Securities Fraud Class Action Lawsuit Filed on their Behalf Pharmaceutical Investing
Awakn Life Sciences Reports Fiscal Fourth Quarter and Fiscal Year January 31, 2022, Results Psychedelics Investing
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amgen Inc. - AMGN Market News
Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model
Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update
